Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 4 | 6 |
| 2010 | 2 | 6 | 8 |
| 2011 | 6 | 2 | 8 |
| 2012 | 4 | 0 | 4 |
| 2013 | 3 | 6 | 9 |
| 2014 | 6 | 5 | 11 |
| 2015 | 6 | 3 | 9 |
| 2016 | 3 | 3 | 6 |
| 2017 | 7 | 0 | 7 |
| 2018 | 11 | 2 | 13 |
| 2019 | 6 | 2 | 8 |
| 2020 | 5 | 5 | 10 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resist Updat. 2023 May; 68:100958.
-
Potential role for protein kinase D inhibitors in prostate cancer. J Mol Med (Berl). 2023 Apr; 101(4):341-349.
-
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma. Br J Cancer. 2022 11; 127(11):1939-1953.
-
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. BMC Med. 2022 08 24; 20(1):257.
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
-
Dramatic Growth of a Vestibular Schwannoma After 16 Years of Postradiosurgery Stability in Association With Exposure to Tyrosine Kinase Inhibitors. Otol Neurotol. 2021 12 01; 42(10):e1609-e1613.
-
Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.
-
Identifying novel putative ERK1/2 inhibitors via hybrid scaffold hopping -FBDD approach. J Biomol Struct Dyn. 2022 09; 40(15):6771-6786.
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
-
Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.